This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Madrigal (MDGL) delivered earnings and revenue surprises of 29.11% and 86.15%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?
by Zacks Equity Research
Devoid of marketed drugs, investors will likely focus on VKTX's pipeline updates when it reports third-quarter results.
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
by Sundeep Ganoria
VKTX continues to generate phenomenal returns, driven by encouraging updates from three promising pipeline programs.
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug
by Zacks Equity Research
FDA's breakthrough therapy designation for SGMT's denifanstat for MASH with moderate-to-advanced liver fibrosis is based on phase IIb FASCINATE-2 study data.
Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report?
by Zacks Equity Research
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viking Surges 342% in the Past Year: How Should You Play the Stock?
by Sundeep Ganoria
VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.
Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?
by Sundeep Ganoria
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line
by Zacks Equity Research
Madrigal (MDGL) posts better than expected second-quarter numbers. It adds nearly $15 million from sales of the first-ever NASH drug Rezdiffra, which is encouraging for a drug launched in April 2024.
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Madrigal (MDGL) delivered earnings and revenue surprises of 5.96% and 286.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
by Sundeep Ganoria
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
by Sundeep Ganoria
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
by Zacks Equity Research
Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.
Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals
by Zacks Equity Research
SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals have been highlighted in this Investment Ideas article.
2 Top Biotech Buyout Candidates
by Andrew Rocco
The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
by Zacks Equity Research
Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
by Zacks Equity Research
Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.
Akero (AKRO) Slumps 63% on Mixed Results From NASH Study
by Zacks Equity Research
Data from a mid-stage study shows that Akero Therapeutics' (AKRO) lead candidate failed to achieve statistical significance in its primary endpoint of fibrosis improvement in cirrhotic NASH patients.
Madrigal (MDGL) to Raise Capital Via Public Offering of $500M
by Zacks Equity Research
Madrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparation of a potential launch of resmetirom in the United States.
Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA
by Zacks Equity Research
Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States.
Intercept (ICPT) NDA for NASH Treatment Gets CRL From FDA
by Zacks Equity Research
Intercept's (ICPT) NDA for obeticholic acid (OCA) gets a complete response letter (CRL) from the FDA for treating pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).
Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days
by Zacks Equity Research
Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers in the phase II ALTITUDE-NASH study in advanced NASH patients.
Intercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation
by Zacks Equity Research
Intercept's (ICPT) NASH treatment does not succeed in getting GIDAC's recommendation for an approval. The committee recommends deferring approval until clinical data from another study is available.
Intercept (ICPT) Down Ahead of GIDAC Meeting for NASH Treatment
by Zacks Equity Research
Intercept (ICPT) falls 14.7% a couple of days before the scheduled GIDAC meeting to review its NASH treatment on concerns of adverse events.
Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study
by Zacks Equity Research
A mid-stage study data shows that Viking Therapeutics' (VKTX) VK2809 achieved reductions in liver fat content in patients with biopsy-confirmed NASH, following 12-weeks of treatment.